Gilead Sciences, Inc. Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.4%projected annual EPS growth
Analyst Coverage
27analysts covering
FY Revenue (est.)
$30.7Bnext fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Next Earnings Release | 29 Oct 2026 |
Monitoring Framework
Key Performance Indicators
FY2026 product sales excluding Veklury guidance lower bound (USD billions) Quarterly29.8
Quarterly product sales excluding Veklury year-over-year growth (percent) Quarterly10.0%
Quarterly HIV product sales year-over-year growth (percent) Quarterly12.0%
Quarterly Trodelvy sales year-over-year growth (percent) Quarterly26.0%
Quarterly Cell Therapy sales year-over-year growth (percent) Quarterly-14.0%
Watch Items
- Yeztugo launch trajectoryAction: If quarterly sales fall below the Q2 2026 baseline, reassess PrEP adoption, access, payer mix and the contribution expected from the lenacapavir franchise.
- Competitive erosion in Cell TherapyAction: If the Q2 2026 contraction persists or worsens, reduce expectations for the legacy CAR-T portfolio and require stronger evidence from anito-cel before assigning acquisition upside.
- Liquidity following acquisition spendingAction: Review debt requirements, integration spending and capacity for dividends and repurchases if liquidity falls below the June 2026 level.
Research as of 29 Aug 2026